Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival - PubMed (original) (raw)
Randomized Controlled Trial
. 2013 Aug 22;122(8):1384-94.
doi: 10.1182/blood-2013-04-496596. Epub 2013 Jul 9.
Affiliations
- PMID: 23838349
- DOI: 10.1182/blood-2013-04-496596
Free article
Randomized Controlled Trial
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
Alan K Burnett et al. Blood. 2013.
Free article
Abstract
Better treatment is required for older patients with acute myeloid leukemia (AML) not considered fit for intensive chemotherapy. We report a randomized comparison of low-dose Ara-C (LDAC) vs the novel nucleoside, clofarabine, in untreated older patients with AML and high-risk myelodysplastic syndrome (MDS). A total of 406 patients with de novo (62%), secondary disease (24%), or high-risk MDS (>10% marrow blasts) (15%), median age 74 years, were randomized to LDAC 20 mg twice daily for 10 days every 6 weeks or clofarabine 20 mg/m(2) on days 1 to 5, both for up to 4 courses. These patients had more adverse demographics than contemporaneous intensively treated patients. The overall remission rate was 28%, and 2-year survival was 13%. Clofarabine significantly improved complete remission (22% vs 12%; hazard ratio [HR] = 0.47 [0.28-0.79]; P = .005) and overall response (38% vs 19%; HR = 0.41 [0.26-0.62]; P < .0001), but there was no difference in overall survival, explained by poorer survival in the clofarabine patients who did not gain complete remission and also following relapse. Clofarabine was more myelosuppressive and required more supportive care. Although clofarabine doubled remission rates, overall survival was not improved overall or in any subgroup. The treatment of patients of the type treated here remains a major unmet need.
Similar articles
- A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. Faderl S, et al. Blood. 2008 Sep 1;112(5):1638-45. doi: 10.1182/blood-2007-11-124602. Epub 2008 Jun 18. Blood. 2008. PMID: 18565853 Free PMC article. Clinical Trial. - European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK. Burnett AK, et al. J Clin Oncol. 2010 May 10;28(14):2389-95. doi: 10.1200/JCO.2009.26.4242. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385984 Clinical Trial. - Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Faderl S, et al. Cancer. 2012 Sep 15;118(18):4471-7. doi: 10.1002/cncr.27429. Epub 2012 Jan 26. Cancer. 2012. PMID: 22282348 Free PMC article. Clinical Trial. - Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
Tran H, Yang D. Tran H, et al. Ann Pharmacother. 2012 Jan;46(1):89-96. doi: 10.1345/aph.1Q295. Epub 2011 Dec 13. Ann Pharmacother. 2012. PMID: 22170975 Review. - Clofarabine for myelodysplastic syndromes.
Tiu RV, Traina F, Sekeres MA. Tiu RV, et al. Expert Opin Investig Drugs. 2011 Jul;20(7):1005-14. doi: 10.1517/13543784.2011.585967. Epub 2011 May 19. Expert Opin Investig Drugs. 2011. PMID: 21591997 Review.
Cited by
- Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CC, Teh TC, Fong CY, Ting SB, Weber D, Benner A, Hill H, Saadati M, Yin J, Stone RM, Garcia-Manero G, Erba HP, Uy GL, Marcucci G, Larson RA, Thomas A, Freeman SD, Almuina NM, Döhner K, Thomas I, Russel NH, Döhner H, Othus M, Estey EH, Walter RB. Appelbaum JS, et al. Leukemia. 2024 Feb;38(2):389-392. doi: 10.1038/s41375-024-02143-8. Epub 2024 Jan 23. Leukemia. 2024. PMID: 38263433 No abstract available. - Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival.
Pommert L, Cooper TM, Gerbing RB, Brodersen L, Loken M, Gamis A, Aplenc R, Alonzo TA, Kolb EA. Pommert L, et al. Cancers (Basel). 2022 Jan 26;14(3):616. doi: 10.3390/cancers14030616. Cancers (Basel). 2022. PMID: 35158884 Free PMC article. - The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed.
Bakunina K, Putter H, Versluis J, Koster EAS, van der Holt B, Manz MG, Breems DA, Gjertsen BT, Cloos J, Valk PJM, Passweg J, Pabst T, Ossenkoppele GJ, Löwenberg B, Cornelissen JJ, de Wreede LC. Bakunina K, et al. Cancer Med. 2022 Feb;11(3):630-640. doi: 10.1002/cam4.4392. Epub 2021 Dec 24. Cancer Med. 2022. PMID: 34953042 Free PMC article. Clinical Trial. - Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence?
Kamphuis JAM, Linschoten M, Cramer MJ, Gort EH, van Rhenen A, Asselbergs FW, Doevendans PA, Teske AJ. Kamphuis JAM, et al. JACC CardioOncol. 2019 Dec 17;1(2):280-290. doi: 10.1016/j.jaccao.2019.09.007. eCollection 2019 Dec. JACC CardioOncol. 2019. PMID: 34396190 Free PMC article. Review. - Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.
Döhner H, Symeonidis A, Deeren D, Demeter J, Sanz MA, Anagnostopoulos A, Esteve J, Fiedler W, Porkka K, Kim HJ, Lee JH, Usuki K, D'Ardia S, Won Jung C, Salamero O, Horst HA, Recher C, Rousselot P, Sandhu I, Theunissen K, Thol F, Döhner K, Teleanu V, DeAngelo DJ, Naoe T, Sekeres MA, Belsack V, Ge M, Taube T, Ottmann OG. Döhner H, et al. Hemasphere. 2021 Aug 2;5(8):e617. doi: 10.1097/HS9.0000000000000617. eCollection 2021 Aug. Hemasphere. 2021. PMID: 34350385 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous